Scarica l'app Stockscreener
2.15
8.59%
0.17
Propanc Biopharma Inc Borsa (PPCB) Ultime notizie
Propanc to acquire $100M of Ethereum to accelerate pipeline - BioWorld MedTech
Propanc Biopharma announces plan to acquire $100 million of Ethereum - MSN
Propanc Biopharma’s $100M Ethereum Allocation: A Strategic Gamble or a Path to Growth? - AInvest
Propanc Biopharma, Inc. Announces $100 Million Ethereum Acquisition Plan to Enhance Growth and Diversification Strategy - Quiver Quantitative
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum - The Manila Times
$100M Ethereum Investment: Cancer Drug Developer Propanc Makes Bold Move into Crypto for Growth Strategy - Stock Titan
Propanc Biopharma Secures $4 Million in Public Offering to Advance Cancer Stem Cell Research - citybuzz -
D. Boral Capital Leads Propanc Biopharma's $4,000,000 Uplisting on Nasdaq - AInvest
D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq:PPCB) in Connection with its $4,000,000 Uplisting - Newswire.com
Propanc Biopharma raises $4 million in Nasdaq debut, plans cancer trials - Investing.com
Propanc Biopharma shares fall 3.26% after-hours following shareholder update on corporate developments and Phase 1B study. - AInvest
Propanc Biopharma provides shareholder update - MarketScreener
Propanc Biopharma prepares for phase 1B cancer drug trial in 2026 By Investing.com - Investing.com South Africa
Propanc Biopharma prepares for phase 1B cancer drug trial in 2026 - Investing.com Nigeria
Propanc Biopharma Provides Shareholder Update - The Manila Times
Propanc Biopharma Announces Shareholder Update and 2025/26 Forecast. - AInvest
Propanc Biopharma: Recent IPO and Up-listing to Nasdaq, Advancing Lead Asset to Phase 1B Study - AInvest
$18.1B Market Potential: Propanc's Novel Cancer Drug PRP Heads to Human Trials After Successful Nasdaq IPO - Stock Titan
Propanc Biopharma Completes Public Offering on Nasdaq - MSN
Propanc Biopharma opens at $4.00 in Nasdaq uplisting - MSN
Biotech’s Big Bang: IPOs, Uplists, and the Short Squeeze Effect - The Globe and Mail
PPCB: Is Recent Nasdaq Uplisting a Game-Changer? - StocksToTrade
Propanc Biopharma’s Surging Market Debut: What’s Next? - timothysykes.com
Stocks Moving Premarket: NBY, AUDD, PPCB And Other Gainers & Losers - RTTNews
Propanc Biopharma shares rise 34.88% premarket after closing a $4 million public offering. - AInvest
Propanc Biopharma closes public offering, uplists to NASDAQ - MSN
Propanc Biopharma Stock Soars 51.23% on Capital Raise - AInvest
Propanc Biopharma shares rise 61.58% premarket after closing a $4 million public offering. - AInvest
Why Did Propanc Biopharma Stock Soar 27.25%? - AInvest
Propanc Biopharma shares rise 52.86% premarket after closing a $4 million public offering. - AInvest
Propanc Biopharma Announces Nasdaq Uplisting, $4M Public Offering - AInvest
Propanc Biopharma shares rise 19.89% after-hours after closing a $4 million public offering. - AInvest
Propanc Biopharma shares rise 21.20% after-hours after closing a $4 million public offering. - AInvest
Propanc Biopharma Raises $4M Through Public Offering, Begins Trading on NASDAQ - AInvest
Propanc Biopharma's NASDAQ Uplisting: A Strategic Leap in Immuno-Oncology's High-Stakes Arena - AInvest
Propanc Biopharma closes $4 million public offering, lists on Nasdaq - Investing.com
Propanc Biopharma closes $4 million public offering, lists on Nasdaq By Investing.com - Investing.com UK
Propanc Biopharma raises $4 million in underwritten public offering. - AInvest
Propanc Biopharma Completes Public Offering, Uplisted to NASDAQ - AInvest
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ - MarketScreener
Cancer Treatment Developer Propanc Biopharma Raises $4M in IPO, Achieves Major Nasdaq Uplisting Milestone - Stock Titan
Propanc Biopharma Plunges 15.04% Amid Tariff Fears - AInvest
Why Propanc stock Is Tumbling In Premarket Today - Asianet Newsable
Precipio Announces Second Quarter 2022 Results, Revenue Up 18% YoY - AInvest
Propanc Biopharma prices $4M stock offering - MSN
Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August - inkl
PPCB Stock Quote - richtv.io
Propanc Biopharma Uplisting: What Lies Ahead? - timothysykes.com
Propanc Biopharma Stock (PPCB) Surges 150% After Nasdaq Uplisting and Public Offering. - AInvest
Stocks Moving Premarket: PPCB, BTAI, TNXP, DAY, TPIC, and Other Gainers & Losers - AInvest
Propanc Biopharma's Nasdaq Uplisting: A Strategic Catalyst for Biotech Innovation - AInvest
PPCB Stock Price and Chart — NASDAQ:PPCB - TradingView
Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering - The Manila Times
Propanc Biopharma's Nasdaq Uplisting and $4M Raise: A Strategic Pivot for Biotech Investors? - AInvest
Propanc Biopharma Appoints New Chief Financial Officer - TipRanks
Propanc Biopharma Enters Securities Purchase Agreement - TipRanks
Propanc Biopharma Issues Promissory Note for Capital - TipRanks
Propanc Biopharma, Inc. Files for 1M Share IPO at $4-$6/sh, Nasdaq Uplisting - Investing.com
PPCBPropanc Bio Latest Stock News & Market Updates - Stock Titan
Propanc Biopharma, Inc. SEC 10-Q Report - TradingView
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):